My Application Form Status

Check the status of your application form with Angel Broking.
  • Companies
  • Everything else
Search
Tube Investments rises after announcing inauguration of bicycle factory in Punjab
Jun 09,2016

The announcement was made after market hours yesterday, 8 June 2016.

Meanwhile, the BSE Sensex was down 173.50 points, or 0.64%, to 26,847.16

On BSE, so far 7,352 shares were traded in the counter, compared with an average volume of 31,922 shares in the past one quarter. The stock hit a high of Rs 469.85 and a low of Rs 460.50 so far during the day. The stock hit a record high of Rs 479 on 2 June 2016. The stock hit a 52-week low of Rs 332 on 29 June 2015. The stock had underperformed the market over the past one month till 8 June 2016, gaining 6.93% compared with Sensexs 7.1% rise. The scrip, however, outperformed the market in past one quarter, rising 17.96% as against Sensexs 9.58% rise.

The mid-cap company has an equity capital of Rs 37.47 crore. Face value per share is Rs 2.

Tube Investments of Indias bicycles division TI Cycles of India announced the inauguration of its state-of-the-art-bicycle manufacturing factory in Rajpura, Punjab today, 9 June 2016 to cater to the growing demand in the North and East Indian markets. TI Cycles of India is one of the leading bicycles manufacturers in India.

Tube Investments of India said that the Rajpura plant is a greenfield project and is set up with the support of the Government of Punjab. The plant has been built with a capital expenditure of Rs 105 crore and has the capacity to manufacture 2.50 lakh cycles per month, with the ability to expand when required, Tube Investments of India said. It is a state-of-the-art plant with the most modern bake-on-bake painting technology, the company said. The plant will have three modern painting lines with German applicators. This new plant at Rajpura will further enhance the companys ability to bring in innovative new products to cater to changing consumer needs. It will also help the company to continually improve the quality of its products on par with best in the world, it added.

Tube Investments of Indias consolidated net profit rose 391.8% to Rs 725.55 crore on 29.4% decline in net sales to Rs 1585.77 crore in Q4 March 2016 over Q4 March 2015.

Tube Investments of India is primarily engaged in the production of steel tubes, cold rolled steel strips and metal sections, as well as bicycles and all critical bicycle components.

Powered by Capital Market - Live News

HCL Tech moves higher on pact with two automotive solution providers
Jun 09,2016

The announcement was made after market hours yesterday, 8 June 2016.

Meanwhile, the S&P BSE Sensex was down 179.76 points or 0.67% at 26,840.90.

On BSE, so far 72,000 shares were traded in the counter as against average daily volume of 3.35 lakh shares in the past one quarter. The stock hit a high of Rs 754.80 and a low of Rs 744.05 so far during the day. The stock had hit a 52-week high of Rs 1,004.95 on 31 July 2015. The stock had hit a 52-week low of Rs 706.50 on 11 May 2016. The stock had underperformed the market over the past one month till 8 June 2016, gaining 2.62% compared with Sensexs 7.1% rise. The scrip had also underperformed the market in past one quarter, sliding 9.13% as against Sensexs 9.58% rise.

The large-cap company has equity capital of Rs 282.11 crore. Face value per share is Rs 2.

Working to enhance HCLs existing Smart Mobility and Vehicle Engineering Services, alliances with Movimento and Rightware will bring invaluable services to HCLs clients, the company said in a statement.

Movimento is a leading provider of over-the-air (OTA) update solutions for automotive solution providers. The partnership between Movimento and HCL will offer automotive lifecycle management, updates and support for on-and off-board software, the company said. The companys partnership with Rightware, a leader in advanced user interface (UI) technology for automotive applications, will enable HCL to help automotive solution providers and Tier-1 manufacturers with all aspects of advanced UI creation, including design, development, systems integration, deployment and support, HCL Technologies said in a statement.

On consolidated basis, HCL Technologies net profit rose 4.01% to Rs 1997.04 crore on 0.01% growth in net sales to Rs 10342.80 crore in Q3 March 2016 over Q2 December 2015.

HCL Technologies is a leading global IT services company working with clients in the areas that impact and redefine the core of their businesses.

Powered by Capital Market - Live News

Lupin drops on reports of product recall
Jun 09,2016

Meanwhile, the S&P BSE Sensex was down 185.49 points or 0.69% at 26,835.17.

On BSE, so far 71,000 shares were traded in the counter as against average daily volume of 2.05 lakh shares in the past one quarter. The stock lost as much as 2.27% at the days low of Rs 1,398 so far during the day. The stock hit a high of Rs 1,430.45 so far during the day. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had hit a record high of Rs 2,127 on 6 October 2015. The stock had underperformed the market over the past one month till 8 June 2016, sliding 9.84% compared with Sensexs 7.1% rise. The scrip had also underperformed the market in past one quarter, declining 21.26% as against Sensexs 9.58% rise.

The large-cap company has equity capital of Rs 90.14 crore. Face value per share is Rs 2.

According to reports, Lupin is recalling 54,472 vials of anti-bacterial injection Ceftriaxone manufactured at its Mandideep facility in Madhya Pradesh due to violation of current good manufacturing norms. Reports suggested that the ongoing voluntary recall is a class III recall and is for the US and Puerto Rico. The recall is being initiated by the companys US arm Lupin Pharmaceuticals Inc covering 54,472 vials of Ceftriaxone for injection in various strengths, as per reports. The company is also recalling 741.171 kg of Ceftriaxone Sodium (Sterile) active pharmaceutical ingredient (API) as its API intermediates failed specifications, reports suggested.

Ceftriaxone for injection USP is used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Lupins consolidated net profit rose 47.5% to Rs 807.08 crore on 34% growth in net sales to Rs 4091.32 crore in Q4 March 2016 over Q4 March 2015.

Lupin is a pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB segment.

Powered by Capital Market - Live News

Lupin drops on reports of drug recall
Jun 09,2016

Meanwhile, the S&P BSE Sensex was down 185.49 points or 0.69% at 26,835.17.

On BSE, so far 71,000 shares were traded in the counter as against average daily volume of 2.05 lakh shares in the past one quarter. The stock was volatile. The scrip hit a low of Rs 1,398 so far during the day. The stock hit a high of Rs 1,430.45 so far during the day. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had hit a record high of Rs 2,127 on 6 October 2015. The stock had underperformed the market over the past one month till 8 June 2016, sliding 9.84% compared with Sensexs 7.1% rise. The scrip had also underperformed the market in past one quarter, declining 21.26% as against Sensexs 9.58% rise.

The large-cap company has equity capital of Rs 90.15 crore. Face value per share is Rs 2.

According to reports, the recall of the drug is a voluntary recall. The recall is being initiated by the companys US arm Lupin Pharmaceuticals Inc. Ceftriaxone for injection USP is used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. The US Food and Drug Administration has reportedly categorized the recall as a class III recall. According to reports, a class III recall is initiated in a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.

Lupins consolidated net profit rose 47.5% to Rs 807.08 crore on 34% growth in net sales to Rs 4091.32 crore in Q4 March 2016 over Q4 March 2015.

Lupin is a pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB segment.

Powered by Capital Market - Live News

Dr Reddys drops as US agency reportedly charges for packaging lapses
Jun 09,2016

Meanwhile, the BSE Sensex was down 164.36 points, or 0.61%, to 26,856.30

On BSE, so far 15,678 shares were traded in the counter, compared with an average volume of 31,597 shares in the past one quarter. The stock hit a high of Rs 3,099 and a low of Rs 3,062.30 so far during the day. The stock hit a record high of Rs 4,382.95 on 20 October 2015. The stock hit a 52-week low of Rs 2,750 on 21 January 2016. The stock had outperformed the market over the past one month till 8 June 2016, gaining 9.22% compared with Sensexs 7.1% rise. The scrip had also underperformed the market in past one quarter, falling 2.64% as against Sensexs 9.58% rise.

The large-cap company has an equity capital of Rs 85.30 crore. Face value per share is Rs 5.

As per reports, the US Consumer Product Safety Commission (US CPSC), a federal regulatory body, has pleaded to the US Department of Justice, seeking civil penalty against Dr Reddys Laboratories (DRL), charging that the drug maker had violated provisions related to child resistant packaging in at least five prescription drugs.

The US CPSC, which is tasked with protecting children and families from risks of injuries or death associated with consumer products, had taken issue with DRLs compliance norms that required special packaging for child resistant blister packs for products sold in the US over several years. As part of its review on 6 June 2016, US CPSC voted 4-1 against DRL for not reporting the risks as per provisions of Consumer Product Safety Act and the Poison Prevention Packaging Act (PPPA), reports added.

As part of its probe that kick-started in 2012, the US CPSC asserted that from 2008 to 2012, DRL sold prescription drugs having unit dose packaging that failed to comply with the US CPSCs special child resistant packaging regulations and also failed to issue general certificates of conformance, reports informed.

Of the global sales of $2.33 billion for financial year ended 31 March 2016, DRL drew $1.16 billion from its North American operations, of which the US accounted for the lions share, as per reports.

Meanwhile, DRL firmly disagreed with the US CPSCs allegations adding that the companys US subsidiary has reaffirmed its commitment to full cooperation with the US government and defended itself against allegations that it failed to comply with applicable special packaging and reporting requirements, reports suggested. DRL believes that it has complied with all applicable requirements of the Consumer Product Safety Act, including applicable packaging and reporting requirements, reports further informed.

Dr Reddys Laboratories consolidated net profit fell 85.6% to Rs 74.60 crore on 2.4% decline in total income to Rs 3792.80 crore in Q4 March 2016 over Q4 March 2015.

Dr Reddys Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Powered by Capital Market - Live News

Dr Reddys drops as US agency charges firm for packaging lapses
Jun 09,2016

Meanwhile, the BSE Sensex was down 164.36 points, or 0.61%, to 26,856.30

On BSE, so far 15,678 shares were traded in the counter, compared with an average volume of 31,597 shares in the past one quarter. The stock hit a high of Rs 3,099 and a low of Rs 3,062.30 so far during the day. The stock hit a record high of Rs 4,382.95 on 20 October 2015. The stock hit a 52-week low of Rs 2,750 on 21 January 2016. The stock had outperformed the market over the past one month till 8 June 2016, gaining 9.22% compared with Sensexs 7.1% rise. The scrip, however, underperformed the market in past one quarter, falling 2.64% as against Sensexs 9.58% rise.

The large-cap company has an equity capital of Rs 85.30 crore. Face value per share is Rs 5.

As per reports, the US Consumer Product Safety Commission (US CPSC), a federal regulatory body, has pleaded to the US Department of Justice, seeking civil penalty against Dr Reddys Laboratories (DRL), charging that the drug maker had violated provisions related to child resistant packaging in at least five prescription drugs. The US CPSC, which is tasked with protecting children and families from risks of injuries or death associated with consumer products, had taken issue with DRLs compliance norms that required special packaging for child resistant blister packs for products sold in the US over several years. As part of its review on 6 June 2016, US CPSC voted 4-1 against DRL for not reporting the risks as per provisions of Consumer Product Safety Act and the Poison Prevention Packaging Act (PPPA), reports added. DRL has reportedly disagreed with the US CPSCs allegations.

Of the global sales of $2.33 billion for financial year ended 31 March 2016, DRL drew $1.16 billion from its North American operations, of which the US accounted for the lions share, according to reports.

Dr Reddys Laboratories consolidated net profit fell 85.6% to Rs 74.60 crore on 2.4% decline in total income to Rs 3792.80 crore in Q4 March 2016 over Q4 March 2015.

Dr Reddys Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr Reddys offers a portfolio of products and services including active pharmaceutical ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Powered by Capital Market - Live News

Infosys declines on worries of short-term volatility in business prospects
Jun 09,2016

Meanwhile, the S&P BSE Sensex was down 157.65 points or 0.58% at 26,863.01.

On BSE, so far 1.86 lakh shares were traded in the counter as against average daily volume of 2.63 lakh shares in the past one quarter. The stock hit a high of Rs 1,228.90 and a low of Rs 1,192.50 so far during the day. The stock had hit a record high of Rs 1,278 on 3 June 2016.The stock had hit a 52-week low of Rs 932.55 on 10 July 2015. The stock had underperformed the market over the past one month till 8 June 2016, gaining 4.81% compared with Sensexs 7.1% rise. The scrip had also underperformed the market in past one quarter, advancing 6.42% as against Sensexs 9.58% rise.

The large-cap company has equity capital of Rs 1148.47 crore. Face value per share is Rs 5.

Infosys chief operating officer (COO) UB Pravin Rao was quoted by the media as saying that the company would face volatility over the next few quarters, due to weaker spending from sectors such as energy and insurance. Rao, however, added that the company was still on track to meet its full-year constant currency revenue growth guidance of 11.5%-13.5% for FY 2017, reports suggested. Rao reportedly said that the management expects some short-term quarterly bumps going ahead. In the last couple of weeks, the results from retail in both US and Europe have not been good, Rao reportedly said. Rao also said that the company was facing a slowdown with its enterprise resource planning (ERP) and business process outsourcing (BPO) businesses, adding that the company was working to turn around those businesses, as per reports.

Meanwhile, shares of Infosys turned ex-dividend today, 9 June 2016, for final dividend of Rs 14.25 per share for the year ended 31 March 2016 (FY 2016).

Infosys consolidated net profit rose 3.8% to Rs 3597 crore on 4.1% growth in net sales to Rs 16550 crore in Q4 March 2016 over Q3 December 2015.

Infosys is a global leader in consulting, technology and outsourcing solutions.

Powered by Capital Market - Live News

Infosys declines on worries over short-term volatility in revenue
Jun 09,2016

Meanwhile, the S&P BSE Sensex was down 157.65 points or 0.58% at 26,863.01.

On BSE, so far 1.86 lakh shares were traded in the counter as against average daily volume of 2.63 lakh shares in the past one quarter. The stock hit a high of Rs 1,228.90 and a low of Rs 1,192.50 so far during the day. The stock had hit a record high of Rs 1,278 on 3 June 2016. The stock had hit a 52-week low of Rs 932.55 on 10 July 2015. The stock had underperformed the market over the past one month till 8 June 2016, gaining 4.81% compared with Sensexs 7.1% rise. The scrip had also underperformed the market in past one quarter, advancing 6.42% as against Sensexs 9.58% rise.

The large-cap company has equity capital of Rs 1148.47 crore. Face value per share is Rs 5.

Rao was quoted as saying at an investor conference in Mumbai that the overall demand remains volatile and Infosys does not expect a recovery in spending from the energy sector before 2017. He said that the company is little bit watchful with regard to the outlook for the retail sector too. Rao also reportedly said that the company is facing a slowdown in its enterprise resource planning (ERP) and business process outsourcing (BPO) businesses, adding that the company is working to turn around those businesses. Rao, however, said that the company remains on track to meet its full-year constant currency revenue growth guidance of 11.5%-13.5% for the year ending 31 March 2017 (FY 2017).

Meanwhile, shares of Infosys turned ex-dividend today, 9 June 2016, for final dividend of Rs 14.25 per share for the year ended 31 March 2016 (FY 2016). Before turning ex-dividend, the stock offered a dividend yield of 1.15% based on the closing price of Rs 1,238.30 on BSE yesterday, 8 June 2016.

Infosys consolidated net profit rose 3.8% to Rs 3597 crore on 4.1% growth in net sales to Rs 16550 crore in Q4 March 2016 over Q3 December 2015.

Infosys is one of the leading information technology outsourcing services providers. The company provides business consulting, information technology and outsourcing services.

Powered by Capital Market - Live News

Lovable Lingerie advances as Reliance Capital Trustee Co buys stake
Jun 09,2016

Meanwhile, the S&P BSE Sensex was down 178.77 points or 0.66% at 26,841.89

On BSE, so far 39,500 shares were traded in the counter as against average daily volume of 16,430 shares in the past one quarter. The stock hit a high of Rs 283.70 and low of Rs 275 so far during the day. The stock had hit a 52-week low of Rs 205 on 23 November 2015. The stock had hit a 52-week high of Rs 324.30 on 4 August 2015.

The small-cap women inner-wear manufacturer has equity capital of Rs 16.80 crore. Face value per share is Rs 10.

Reliance Capital Trustee Co A/c MF bought 6.74 lakh shares at an average price of Rs 205 per share of Lovable Lingerie in a bulk deal on the BSE yesterday, 8 June 2016. Nalanda India Equity Fund sold 8 lakh shares at an average price of Rs 205.28 per share of Lovable Lingerie in a bulk deal on the BSE yesterday, 8 June 2016.

Lovable Lingeries net profit rose 138.3% to Rs 3.17 crore on 41.3% rise in net sales to Rs 36.08 crore in Q4 March 2016 over Q4 March 2015.

Lovable Lingerie is one of Indias leading womens innerwear manufacturers. The companys products include brassieres, panties, slips / camisoles, homewear, shapewear, foundation garments and sleepwear products.

Powered by Capital Market - Live News

BPCL gains after RBI raises foreign investment ceiling
Jun 09,2016

Meanwhile, the S&P BSE Sensex was down 184.45 points or 0.68% at 26,836.21.

On BSE, so far 37,000 shares were traded in the counter as against average daily volume of 84,539 shares in the past one quarter. The stock hit a high of Rs 999 and a low of Rs 988.60 so far during the day. The stock had hit a record high of Rs 1,032 on 3 June 2016. The stock had hit a 52-week low of Rs 732.20 on 23 February 2016. The stock had underperformed the market over the past one month till 8 June 2016, gaining 4.32% compared with Sensexs 7.1% rise. The scrip, however, outperformed the market in past one quarter, surging 19.42% as against Sensexs 9.58% rise.

The large-cap company has equity capital of Rs 723.08 crore. Face value per share is Rs 10.

It may be recalled that BPCL last week got shareholders nod for raising the ceiling on investment by FIIs in the companys equity.

BPCLs net profit fell 10.6% to Rs 2549.08 crore on 14% decline in net sales to Rs 44145.54 crore in Q4 March 2016 over Q4 March 2015.

BPCL is a state-run oil refining-cum-marketing company. The Government of India currently holds 54.93% stake in BPCL (as per the shareholding pattern as on 31 March 2016).

Powered by Capital Market - Live News

Tata Motors inches up after reporting decent wholesales for May
Jun 09,2016

The announcement was made after market hours yesterday, 8 June 2016.

Meanwhile, the S&P BSE Sensex was down 101.62 points or 0.38% at 26,919.04.

On BSE, so far 50,000 shares were traded in the counter as against average daily volume of 13.25 lakh shares in the past two weeks. The stock hit a high of Rs 469 so far during the day, which is a 52-week high for the counter. The stock hit a low of Rs 465.95 so far during the day. The stock had hit a 52-week low of Rs 266 on 11 February 2016.

The large-cap company has equity capital of Rs 577.44 crore. Face value per share is Rs 2.

Global wholesales of all Tata Motors commercial vehicles and Tata Daewoo range rose 11% to 32,375 units in May 2016 over May 2015. Global wholesales of all passenger vehicles rose 10% to 55,039 units in May 2016 over May 2015.

Tata Motors consolidated net profit jumped 201.6% to Rs 5177.06 crore on 18.8% growth in net sales to Rs 79926.12 crore in Q4 March 2016 over Q4 March 2015.

Tata Motors is a market leader in commercial vehicles in India. The companys British unit Jaguar Land Rover sells premium luxury cars.

Powered by Capital Market - Live News

Bharat Forge gains as joint venture company signs contract with NTPC
Jun 08,2016

The announcement was made after market hours yesterday, 7 June 2016.

Meanwhile, the S&P BSE Sensex was up 25.24 points or 0.09% at 27,034.91

On BSE, so far 1.13 lakh shares were traded in the counter as against average daily volume of 75,769 shares in the past one quarter. The stock hit a high of Rs 773 and a low of Rs 758.50 so far during the day. The stock had hit a 52-week low of Rs 705 on 24 May 2016. The stock had hit a 52-week high of Rs 1,292.50 on 20 August 2015. The stock had underperformed the market over the past one month till 7 June 2016, falling 4.03% compared with 7.06% gains in the Sensex. The scrip also underperformed the market in past one quarter, falling 8.35% as against Sensexs 9.59% gains.

The large-cap company has equity capital of Rs 46.56 crore. Face value per share is Rs 2.

Alstom Bharat Forge Power (ABFPL), the joint venture company between GE and Bharat Forge, has signed a contract worth $219 million (about Rs 1495 crore) with NTPC. The joint venture company will supply two units of 800 megawatts (MW) ultra-supercritical steam turbine generator islands, on engineering, procurement and construction (EPC) basis, along with related civil work for the Telangana Super Thermal Power Project Phase-1 near Ramagundam, Telangana. The equipment for the project will be manufactured majorly at ABFPLs manufacturing facility at Sanand, Gujarat.

ABFPL was created to participate in the Indian market of turbines islands (steam turbines and generators, heat exchangers and all associated equipment). GE has a majority stake in this joint venture. The join venture company manufactures 300-800 MW subcritical and supercritical equipment with an annual capacity of 4000 MW.

Bharat Forges net profit fell 19% to Rs 164.52 crore on 17.4% decline in net sales to Rs 987.07 crore in Q4 March 2016 over Q4 March 2015.

Bharat Forge is the flagship company of Kalyani Group. It is a global provider of high performance, innovative, safety & critical components and solutions to various industrial sectors including automotive, oil & gas, power, construction & mining, aerospace and rail & marine.

Powered by Capital Market - Live News

M&M inches up on onset of monsoon rains in Kerala
Jun 08,2016

Meanwhile, the S&P BSE Sensex was up 26.98 points or 0.1% at 27,036.65.

On BSE, so far 75,000 shares were traded in the counter as against average daily volume of 1.55 lakh shares in the past two weeks. The stock rose as much as 1.38% at the days high of Rs 1,397 so far during the day. The stock rose 0.15% at the days low of Rs 1,380 so far during the day. The stock had hit a record high of Rs 1,441.45 on 7 August 2015. The stock had hit a 52-week low of Rs 1,092 on 12 February 2016.

Shares of Mahindra & Mahindra (M&M) have risen 3.38% in the preceding three trading sessions to settle at Rs 1,377.85 yesterday, 7 June 2016, from its close of Rs 1,332.70 on 2 June 2016, on hopes of good monsoon rains. Good rains may boost demand for tractors. M&M is the largest tractor maker in India in terms of market share.

There has been delay in the onset of the monsoon rains in Kerala this year from the normal onset date which is 1 June. The arrival of the rains at the Kerala coast marks the onset of the June-September southwest monsoon season in India.

Quantitatively, monsoon season rainfall for the country as a whole is likely to be 106% of the long period average (LPA) with a model error of plus/minus 4%, the IMD said after trading hours on 2 June 2016. In its first stage forecast issued on 12 April 2016, the IMD had forecast rainfall to be 106% of the LPA with a model error of plus/minus 5%.

M&Ms net profit rose 6% to Rs 583.73 crore on 14.8% growth in net sales to Rs 10666.43 crore in Q4 March 2016 over Q4 March 2015.

The Mahindra Group enjoys a leadership position in tractors, utility vehicles, information technology, financial services and vacation ownership. In addition, Mahindra enjoys a strong presence in the agribusiness, aerospace, components, consulting services, defence, energy, industrial equipment, logistics, real estate, retail, steel, commercial vehicles and two-wheeler industries.

Powered by Capital Market - Live News

Alphageo (India) hits 52-week high
Jun 08,2016

Meanwhile, the S&P BSE Sensex was down 31.69 points or 0.12% at 26,977.98

On BSE, so far 1.16 lakh shares were traded in the counter as against average daily volume of 6,752 shares in the past one quarter. The stock hit a high of Rs 792.10 so far during the day, which is a 52-week high for the counter. The stock hit a low of Rs 756 so far during the day. The stock had hit a 52-week low of Rs 268 on 24 August 2015. The stock had outperformed the market over the past one month till 7 June 2016, rising 15.1% compared with 7.06% gains in the Sensex. The scrip also outperformed the market in past one quarter, gaining 20.46% as against Sensexs 9.59% gains.

The small-cap company has equity capital of Rs 5.63 crore. Face value per share is Rs 10.

Shares of Alphageo (India) rose by maximum permissible daily limit of 20% to settle at Rs 660.10 yesterday, 7 June 2016 after the company announced that it has secured letters of award of contracts from ONGC. The announcement was made during market hours yesterday, 7 June 2016.

Alphageo (India) said it has secured various letters of award of contracts from ONGC for acquisition of 2D seismic data in un-appraised on land areas of Indian sedimentary basins of India as a part of the National Seismic Program by March 2019. The estimated total value of the awards received is about Rs 1482 crore inclusive of taxes, Alphageo (India).

Alphageo (India)s consolidated net profit surged 9052.4% to Rs 19.22 crore on 429.7% growth in total income to Rs 71.02 crore in Q4 March 2016 over Q4 March 2015.

Alphageo (India) is the largest onshore integrated seismic service provider in the private sector and enjoys a market leadership in seismic survey.

Powered by Capital Market - Live News

Alphageo (India) soars after large order win
Jun 08,2016

Meanwhile, the S&P BSE Sensex was down 31.69 points or 0.12% at 26,977.98,

On BSE, so far 1.16 lakh shares were traded in the counter as against average daily volume of 6,752 shares in the past one quarter. The stock hit a fresh 52-week high today, 8 June 2016. The stock hit a low of Rs 756 so far during the day. The stock had hit a 52-week low of Rs 268 on 24 August 2015. The stock had outperformed the market over the past one month till 7 June 2016, rising 15.1% compared with 7.06% gains in the Sensex. The scrip also outperformed the market in past one quarter, gaining 20.46% as against Sensexs 9.59% gains.

The small-cap company has equity capital of Rs 5.63 crore. Face value per share is Rs 10.

Shares of Alphageo (India) rose by maximum permissible daily limit of 20% to settle at Rs 660.10 on BSE yesterday, 7 June 2016, after the company announced that it has secured letters of award for contracts aggregating Rs 1482 crore from ONGC. The contracts pertain to acquisition of 2D seismic data in un-appraised on land areas of Indian sedimentary basins as a part of the National Seismic Program. The company has initiated the necessary steps to execute the contracts.

Alphageo (India)s consolidated net profit surged 9052.4% to Rs 19.22 crore on 442.1% growth in total income to Rs 71.02 crore in Q4 March 2016 over Q4 March 2015.

Alphageo (India) is the largest onshore integrated seismic service provider in the private sector and enjoys a market leadership in seismic survey.

Powered by Capital Market - Live News